= Emerging. More than 5 years before clinical availability. (26.62%)
= Expected to be clinically available in 1 to 4 years. (38.91%)
= Clinically available now. (34.47%)
MSACL 2020 US : Lassman

MSACL 2020 US Abstract

Keynote Presentation

Topic: Proteomics

Podium Presentation in Room 5 on Thursday at 9:00 (Chair: Mari DeMarco)

The Changing Landscape of Immune-oncology and How Mass Spectrometry Might Help Guide Patient Care

Michael Lassman (Presenter)
Merck & Co

Authors: Michael Lassman
Merck and Co

Abstract

Immune-oncology therapeutics take advantage of the body’s immune system to fight cancers. Unlike chemotherapy, which acts directly on the tumor. Immune-oncology therapies, specifically anti-PD-1 therapies have been demonstrated to be broadly successful across many indications and tumor types. Patients’ and family members’ lives have been changed as a result of these therapies; but not all patients benefit similarly or achieve complete responses. Analytical platforms such as IHC and Genomic analyses have been widely used to predict the likelihood of a patient to respond to anti-PD-1 therapy. Why not Mass Spectrometry?

Single-plex IHC is readily available but is limited in terms of multiplexing and is not quantitative. Genomic analyses can measure thousands of genes from a limited amount of tumor material and is an attractive tool relative to traditional IHC analyses despite that it cannot directly measure whether gene expression represents protein expression. Mass Spectrometry is an attractive quantitative platform as it is readily multiplexed and has been demonstrated to be capable of the simultaneous measurement of multiple proteins, including post-translational modifications, from a single sample. Furthermore, as mass spectrometry is quantitative, the platform could readily measure changes in tumors, indicating the effect of an immune-oncology therapy and potentially driving patient care.

Here, we will describe advances in immune-oncology that have demonstrated this to be such a promising field. We describe biomarker assays that have been critical to identifying patient populations most likely to receive benefit or that drive the use of combination therapies. We highlight some limitations to current methodologies as well as current demonstrations of the use of mass spectrometry to “fill in the gaps”.


Financial Disclosure

DescriptionY/NSource
Grantsno
SalaryyesMerck & Co
Board Memberno
Stockyes Merck & Co
Expensesno
IP Royaltyno

Planning to mention or discuss specific products or technology of the company(ies) listed above:

no